Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia

Movement Disorders

Volumn 21, Issue 10, 2006, Pages 1663-1666

  Gurevich, Tanya Y ^a   Shabtai, Herzel ^a   Korczyn, Amos D ^a   Simon, Ely S ^b   Giladi, Nir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NeuroTrax Corporation   (United States)

Author keywords

Cholinesterase inhibitors; Cognitive functions; Dementia; Parkinson's disease; Rivastigmine; Tremor

Indexed keywords

DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; RIVASTIGMINE; SELEGILINE;

ACCELEROMETRY; AGED; AMPLITUDE MODULATION; ARTICLE; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DEMENTIA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; HALLUCINATION; HAND TREMOR; HUMAN; HYPERSALIVATION; MAXIMUM PERMISSIBLE DOSE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA; DRUG THERAPY, COMBINATION; FEMALE; FUNCTIONAL LATERALITY; HUMANS; LEVODOPA; MALE; MENTAL STATUS SCHEDULE; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHENYLCARBAMATES; TREMOR;

EID: 33751006120     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20971     Document Type: Article

References (21)

1. Korczyn AD, Inzelberg R, Treves TA, et al. Dementia of Parkinson's disease. Adv Neurol 1987;45:399-403.
2. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 2000;107:59-71.
3. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease: II. Treatment. Am Fam Physician 2002;65:2525-2534.
4. McKeith IG, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
5. Aarsland D, Cummings J, Larsen J. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:184-191.
6. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003;108:368-373.
7. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;35:2509-2518.
8. Hughes A, Daniel S, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease - a clinico pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
9. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
10. American-Psychiatric-Association. Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Fahn S, Elton RL, Members of the UPDRS Development Committee. The unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson's Disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p 153-163.
13. Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
14. Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001; 56:1712-1721.
15. Golan D, Giladi N, Thorne R, Korczyn AD, Simon ES. Subdivision of essential tremor patients according to physiologic characteristics. Acta Neurol Scand 2004;109:393-397.
16. Korczyn AD, Nisipeanu P. Newer therapies for Parkinson's disease. Neurol Neurochir Pol 1996;30:105-111.
17. Korczyn AD. Dopaminergic drugs in development for Parkinson's disease. Adv Neurol 2003;91:267-271.
18. Aarsland D, Laake K, Larsen J, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.
19. Richard IH, Justus AW, Greig NH, Marshall F, Kurlan R. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol 2002;25:296-299.
20. Arsland D, Engedal KA, Nygaard HA, Louhija J, Ulstein I, Holm M. Cholinesterase inhibitors in Norway - effectiveness and side effects in clinical practice. Tidsskr Nor Laegeforen 2003;123:1500-1503.
21. Beuter A, Edwards R, Boucher A. Physiological tremor: does handedness make a difference? Int J Neurosci 2000;101:9-19.